Tech Company Financing Transactions

Tigris Pharmaceuticals Funding Round

NGN Capital and Wexford Capital participated in a $16 million Series B funding round for Tigris Pharmaceuticals. The round was announced on 1/16/2007.

Transaction Overview

Announced On
Transaction Type
Venture Equity
Series B

NGN Capital (Lead Investor) (Georg Nebgen)

Wexford Capital (Paul Mieyal)

Proceeds Purpose
The proceeds from the financing will be used primarily to advance the development of Tigris' clinical and pre-clinical product pipeline, including its lead compound, A-007, a topical gel for the treatment of cervical intra-epithelial neoplasia (CIN) resulting from the human papilloma virus (HPV). A-007 has completed enrollment of two registration trials in Mexico in patients with high grade CIN (CIN II and III) and is currently enrolling patients in a large Phase II clinical trial in the U.S. Tigris has also completed enrollment on a Phase I/II clinical trial in patients with anal neoplasia (ASIL). If successfully developed, A-007 represents a non-invasive alternative to the current standard of care, loop electrosurgical excision surgery (LEEP), and could complement prophylactic vaccines to reduce the incidence of cervical cancer.

Company Information

Company Status
Out of Business
Mailing Address
3359 Woods Edge Circle 103
Bonita Springs, FL 34134
Email Address
Tigris Pharmaceuticals, Inc. is a privately held biopharmaceutical company that develops therapeutic technologies to treat oncology, infectious diseases and other areas of unmet medical need. Tigris is currently conducting a Phase II clinical study for A-007, its topical treatment for pre-cancerous and cancerous anogenital lesions associated with HPV.
Tigris Pharmaceuticals LinkedIn Company Profile
Social Media
Tigris Pharmaceuticals Company Twitter Account
Company News
Tigris Pharmaceuticals News
Tigris Pharmaceuticals on Facebook
Tigris Pharmaceuticals on YouTube

Management Team

Email & Social
Chief Executive Officer
Edmundo Muniz
  Edmundo Muniz LinkedIn Profile  Edmundo Muniz Twitter Account  Edmundo Muniz News  Edmundo Muniz on Facebook
Chief Medical Officer
Joseph Pergolizzi
  Joseph Pergolizzi LinkedIn Profile  Joseph Pergolizzi Twitter Account  Joseph Pergolizzi News  Joseph Pergolizzi on Facebook
VP - Operations
Alexander Mironov
  Alexander Mironov LinkedIn Profile  Alexander Mironov Twitter Account  Alexander Mironov News  Alexander Mironov on Facebook



Browse more venture capital transactions:

Prev: 1/15/2007: ATD venture capital transaction
Next: 1/16/2007: Twelvefold Media venture capital transaction


Share this article


About Our VC Transactions Data

We do our best to report on every notable VC transaction. VC transactions reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with, an affiliated venture.


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities


Business Glossary